Human Dermal Fibroblasts As A Novel Therapeutic Agent For Neuroinflammation
CSEF · 2023 Biochemistry/ Molecular Biology Second Award
Overview
Background: Rising healthcare costs and negative impacts on quality of life are challenges faced by the elderly suffering from neurodegenerative diseases, involving neuroinflammation such as Alzheimer’s and Dementia. Current therapeutic regimes can mitigate the effects of neuroinflammation but not reverse it. Mesenchymal Stem Cells (MSCs) can reverse neuroinflammation, but are not commercially viable. Human Dermal Fibroblasts exhibit similar anti-inflammatory, immunomodulatory and differentiation potential as MSCs for reversing neuroinflammation, and are easily harvested. This project presents a breakthrough novel therapeutic agent based on human dermal fibroblasts, as it was hypothesized that they will reverse neuroinflammation. Methods: Ten C57BL/6J mice were intraperitoneally injected with 2 mg/kg of Lipopolysaccharide (LPS) of the serotype O55:B5 to induce acute neuroinflammation. After one hour, mice were injected through the eye with 0.1 mL of human dermal fibroblasts (5*105). Blood collection occurred before LPS administration, between LPS and fibroblast administration, and two hours post-fibroblast administration. The Novel Object Recognition Test (NORT) and Enzyme-Linked Immunosorbent Assay (ELISA) tested for changes in recognition memory and Interleukin-1Beta levels, respectively. Results: Optical density readings from the ELISA showed an increase in IL-1β one hour post-LPS administration and a decrease in IL-1β post-fibroblast administration. Mice on average mimicked the wild-type NORT expectation of spending significantly more time with the novel object. Conclusion: Fibroblasts decrease neuroinflammation, decrease IL-1β cytokine levels and normalize NORT memory. Future steps to advance translational efforts include replicate cohorts, different behavioral tests, more inflammatory cytokine analyses, and immunohistochemistry of brain tissue.
Source coverage
This record comes from a published award list, not a complete project archive. Its abstract comes from CSEF's public project showcase as archived by the Internet Archive before judging (https://web.archive.org/web/20230401224130/https://ca-csef.zfairs.com/showcase/ShowcaseInfo?f=838e60b7-ea75-46e8-865c-fde4864244b3); the version presented may differ.
Awards (1)
Competition history
- CSEF 2023
Resources
Related projects
CSEF · 2006
Enhancing Mechanotransduction of Aging Human Dermal Fibroblasts
CSEF · 2010
Alzheimer's and Inflammation: Exploring Enzymatic Pathways Involved in Beta Amyloid Induced TNF alpha Production
ISEF · 2016
Moving Towards the Cure: The Effect of Neuroinflammation and Microglial Activity on Alzheimer's Pathology and the Development of Therapeutics for Their Mitigation in the TG4510 Mouse Model (A Third Year Study)
ISEF · 2015
Repurposing CNI-1493 to Treat Alzheimer's Disease: Attenuation of Intracellular Amyloid Beta in vitro and in vivo
ISEF · 2015
Moving Towards the Cure: The Effects of LPS-Induced Inflammation Response on the Regulation of the MAPT Gene in Alzheimer's Disease, a Novel Second Year in vitro Study
ISEF · 2025
Paving the Path to the Impossible: Regenerating Neurons Using Prostaglandin E2 Regulation as a Therapeutic Strategy
ISEF · 2026
Human Stem Cell Derived Extracellular Vesicles for the Treatment of Neurodegenerative Disease
CSEF · 2015
Examining the Role of CXCR4 on the Differential Migration of ESC-Derived Neural Stem Cells
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects